<?xml version="1.0" encoding="UTF-8"?>
<p>Lembo and Cavalli [
 <xref rid="B18-pharmaceutics-12-00171" ref-type="bibr">18</xref>] present the current status up to 2010 in the nanoparticulate delivery systems in antiviral therapy area, highlighting their perspective on the challenges that must be tackled before the nanotechnology can be translated into clinical use as safe and effective antiviral formulations. Therefore, the nanoparticulate antiviral systems synthesised up to 2010 consisted mainly of micelles, polymeric NPs, solid lipid NPs (SLNs), nanostructured lipid carriers (NLCs), liposomes, nanocapsules, vesicles, dendrimers, nanogels, cyclodextrin-based systems and emulsions.
</p>
